Resumen de Institute for oneworld health.

• Focuses on the efforts of the nonprofit drug firm, Institute for OneWorld Health, to develope affordable medicine for the developing world. Starting in mid-2003 and through this year, the Institute for OneWorld Health carried out clinical trials in India to treat visceral leishmaniasis with the antibiotic paromomycin. Visceral leishmaniasis, a deadly illness transmitted by the bite of an infected sand fly, kills 200,000 people every year. An estimated 1.5 million people have the infection, and some 500,000 new cases arise annually, primarily in India, Bangladesh, Nepal, Sudan and Brazil. On another of its many fronts, the company received a $1.4-million grant in July from the Bill and Melinda Gates Foundation to support development of vaccines for the prevention of the scourge of malaria.